{"id":"https://openalex.org/W2889753198","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.1512","title":"Implementing universal genetic counseling (GC) and multigene germline testing (MGT) for pancreatic cancer (PC) patients (pts).","display_name":"Implementing universal genetic counseling (GC) and multigene germline testing (MGT) for pancreatic cancer (PC) patients (pts).","publication_year":2018,"publication_date":"2018-05-20","ids":{"openalex":"https://openalex.org/W2889753198","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.1512","mag":"2889753198"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.15_suppl.1512","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.1512","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.1512","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005140127","display_name":"Matthew B.B. Yurgelun","orcid":"https://orcid.org/0000-0002-6184-9273","observed_orcids":["https://orcid.org/0000-0002-6184-9273"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew B. Yurgelun","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025592253","display_name":"Anu B. Chittenden","orcid":"https://orcid.org/0000-0002-7037-3430","observed_orcids":["https://orcid.org/0000-0002-7037-3430"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anu B. Chittenden","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082845071","display_name":"Chinedu I. Ukaegbu","orcid":"https://orcid.org/0000-0002-1629-2824","observed_orcids":["https://orcid.org/0000-0002-1629-2824"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chinedu I. Ukaegbu","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009517468","display_name":"Tara G. Dhingra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tara G. Dhingra","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073536456","display_name":"Shraddha Gaonkar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shraddha Gaonkar","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074472273","display_name":"Jiliane Sotelo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jiliane Sotelo","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044352034","display_name":"Douglas Adam Rubinson","orcid":"https://orcid.org/0000-0002-5337-5231","observed_orcids":["https://orcid.org/0000-0002-5337-5231"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas Adam Rubinson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053848207","display_name":"Nadine J. McCleary","orcid":"https://orcid.org/0000-0003-2377-8301","observed_orcids":["https://orcid.org/0000-0003-2377-8301"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nadine Jackson McCleary","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087484173","display_name":"Thomas E. Clancy","orcid":"https://orcid.org/0000-0002-0949-4874","observed_orcids":["https://orcid.org/0000-0002-0949-4874"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas E. Clancy","raw_affiliation_strings":["Brigham and Women's Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital, Boston, MA;","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045494904","display_name":"Thomas Adam Abrams","orcid":"https://orcid.org/0000-0003-3101-1573","observed_orcids":["https://orcid.org/0000-0003-3101-1573"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Adam Abrams","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018655814","display_name":"James M. Cleary","orcid":"https://orcid.org/0000-0001-7213-3951","observed_orcids":["https://orcid.org/0000-0001-7213-3951"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James M. Cleary","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079786237","display_name":"Audrey Madigan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Audrey P. Madigan","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028547202","display_name":"Lauren K. Brais","orcid":"https://orcid.org/0000-0003-1069-0407","observed_orcids":["https://orcid.org/0000-0003-1069-0407"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lauren K. Brais","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004799675","display_name":"Kimberly J. Perez","orcid":"https://orcid.org/0000-0002-5745-2994","observed_orcids":["https://orcid.org/0000-0002-5745-2994"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kimberly Perez","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047496278","display_name":"Brian Matthew Wolpin","orcid":"https://orcid.org/0000-0002-0455-1032","observed_orcids":["https://orcid.org/0000-0002-0455-1032"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian M. Wolpin","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079620607","display_name":"Sapna Syngal","orcid":"https://orcid.org/0000-0001-5487-7471","observed_orcids":["https://orcid.org/0000-0001-5487-7471"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sapna Syngal","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"15_suppl","first_page":"1512","last_page":"1512"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.9434000253677368,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.9434000253677368,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.03370000049471855,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11369","display_name":"Genetic factors in colorectal cancer","score":0.019600000232458115,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.9139999747276306},{"id":"https://openalex.org/keywords/hereditary-cancer-risk-assessment","display_name":"hereditary cancer risk assessment","score":0.8650000095367432},{"id":"https://openalex.org/keywords/germline-mutations","display_name":"germline mutations","score":0.703000009059906},{"id":"https://openalex.org/keywords/brca1","display_name":"BRCA1","score":0.9570000171661377},{"id":"https://openalex.org/keywords/brca2","display_name":"BRCA2","score":0.9990000128746033},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8259999752044678},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.8119999766349792},{"id":"https://openalex.org/keywords/cascade-testing","display_name":"cascade testing","score":0.8970000147819519},{"id":"https://openalex.org/keywords/implementation-barriers","display_name":"implementation barriers","score":0.6840000152587891},{"id":"https://openalex.org/keywords/atm","display_name":"ATM","score":0.5120000243186951},{"id":"https://openalex.org/keywords/palb2","display_name":"PALB2","score":0.9879999756813049},{"id":"https://openalex.org/keywords/stk11","display_name":"STK11","score":0.8429999947547913},{"id":"https://openalex.org/keywords/pms2","display_name":"PMS2","score":0.8050000071525574},{"id":"https://openalex.org/keywords/niobium-nitride","display_name":"niobium nitride","score":0.9760000109672546}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9165346026420593},{"id":"https://openalex.org/C2776135927","wikidata":"https://www.wikidata.org/wiki/Q5242559","display_name":"Referral","level":2,"score":0.654900312423706},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5403845906257629},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5145384669303894},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.48379677534103394},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.4832037687301636},{"id":"https://openalex.org/C2780673598","wikidata":"https://www.wikidata.org/wiki/Q285223","display_name":"Genetic testing","level":2,"score":0.46988868713378906},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.34335893392562866}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.15_suppl.1512","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.1512","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.1512","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.5600000023841858,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2590224211","https://openalex.org/W2371771839","https://openalex.org/W2380083969","https://openalex.org/W2419671669","https://openalex.org/W2749944573","https://openalex.org/W135094908","https://openalex.org/W1996905147","https://openalex.org/W1981626029","https://openalex.org/W2438940351","https://openalex.org/W2397088966"],"abstract_inverted_index":{"1512":[0],"Background:":[1],"MGT":[2,24,87,125,165,190,208,276],"will":[3],"identify":[4],"cancer":[5,53,248],"susceptibility":[6],"gene":[7],"variants":[8],"in":[9,61,96,242,312,320,356],"4-10%":[10],"of":[11,25,50,119,194,206,252,257,309,323,338,342,353],"unselected":[12],"PC":[13,27,58,82,98,120,136,158,313,329],"pts.":[14],"Such":[15],"data":[16,112],"have":[17,293],"prompted":[18],"calls":[19],"for":[20,56,84,140,152,302,328],"universal":[21,51,310,354],"GC":[22,85,106,123,161,180],"and":[23,33,86,104,110,124,154,162,166,199,227,263,290,318,331],"all":[26,57,81],"pts,":[28],"but":[29],"the":[30,48,72,130,170,303,321,350],"real-world":[31,351],"benefits":[32],"barriers":[34],"to":[35,46,79,101,164,179,217,349],"implementing":[36],"such":[37],"systematic":[38],"testing":[39,301],"are":[40,297,326],"unknown.":[41],"This":[42],"study\u2019s":[43],"aim":[44],"was":[45,94,181],"study":[47,132,167],"implementation":[49,308],"hereditary":[52],"risk":[54],"assessment":[55],"pts":[59,83,121,137,159,314,330],"seen":[60,139],"an":[62],"academic":[63],"oncology":[64,142],"practice.":[65],"Methods:":[66],"All":[67],"gastrointestinal":[68],"medical":[69,141],"oncologists":[70],"at":[71,146],"Dana-Farber":[73],"Cancer":[74],"Institute":[75],"(DFCI)":[76],"were":[77,113,138,150,215,238],"recommended":[78],"refer":[80],"beginning":[88],"12/2016.":[89],"A":[90],"special":[91],"referral":[92,107,344],"sheet":[93],"placed":[95],"new":[97,143],"pt":[99],"charts":[100],"remind":[102],"providers":[103],"streamline":[105],"workflows.":[108],"Clinical":[109,307,358],"germline":[111,219],"collected":[114],"on":[115,235,275,280],"a":[116,346],"consecutive":[117],"cohort":[118],"undergoing":[122,287],"from":[126,175],"3/1/2017-1/31/2018.":[127],"Results:":[128],"Over":[129],"11-month":[131],"period,":[133],"443":[134],"(43.9/month)":[135],"patient":[144,243],"visits":[145],"DFCI,":[147],"114":[148],"(10.4/month)":[149],"referred":[151],"GC,":[153],"92":[155,171],"(8.4/month)":[156],"eligible":[157],"underwent":[160,189],"consented":[163],"enrollment.":[168],"Among":[169],"participants,":[172],"median":[173],"time":[174],"first":[176,196],"DFCI":[177,197],"appointment":[178],"44":[182],"days":[183,193,205],"(IQR":[184],"23-142":[185],"days),":[186],"33":[187],"(35.9%)":[188],"within":[191,203],"30":[192,204],"their":[195,332],"appointment,":[198],"4":[200],"(4.3%)":[201],"died":[202,285],"receiving":[207],"results.":[209],"8/92":[210],"(8.7%;":[211],"95%":[212],"CI":[213],"2.9-14.5%)":[214],"found":[216],"carry":[218],"mutations":[220,324],"(2":[221,278],"BRCA1,":[222],"2":[223,284],"BRCA2,":[224],"1":[225,229,231,233],"ATM":[226],"PALB2,":[228],"NBN,":[230],"PMS2,":[232],"STK11)":[234],"MGT.":[236],"There":[237],"no":[239],"significant":[240],"differences":[241],"age,":[244],"sex,":[245],"race,":[246],"personal":[247],"history,":[249],"family":[250,255,294,334],"history":[251,256],"PC,":[253],"or":[254],"other":[258],"cancers":[259],"between":[260],"mutation":[261],"carriers":[262,267],"non-carriers.":[264],"4/8":[265],"(50%)":[266],"received":[268],"targeted":[269,288],"therapy":[270],"(eg,":[271],"PARP":[272],"inhibitors)":[273],"based":[274],"results":[277,319],"remain":[279],"1st":[281],"line":[282],"chemotherapy;":[283],"without":[286],"therapy)":[289],"5/8":[291],"(63%)":[292],"members":[295],"who":[296],"actively":[298],"pursuing":[299],"cascade":[300],"identified":[304],"mutation.":[305],"Conclusions:":[306],"GC/MGT":[311,355],"is":[315,345],"potentially":[316],"feasible":[317],"detection":[322],"that":[325],"actionable":[327],"at-risk":[333],"members.":[335],"In":[336],"spite":[337],"streamlined":[339],"workflows,":[340],"lack":[341],"oncologist":[343],"critical":[347],"barrier":[348],"efficacy":[352],"PC.":[357],"trial":[359],"information:":[360],"NCT03060720.":[361]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2025-10-10T00:00:00"}